Groundbreaking Phase II Study Shows Ligufalimab Offers Significant Benefits for Acute Myeloid Leukemia Patients

Ligufalimab's Impact on Acute Myeloid Leukemia: A Detailed Overview

In a groundbreaking study presented at the European Hematology Association Congress in 2026, Akeso, Inc. revealed compelling Phase II trial results for ligufalimab, a novel anti-CD47 monoclonal antibody, in treating patients with acute myeloid leukemia (AML). This research highlights not only the potential of ligufalimab in improving patient outcomes but also marks a significant step forward in the management of AML, particularly for those who cannot undergo intensive chemotherapy.

Study Design and Objectives

The Phase II trial (AK117-206) was a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of ligufalimab when used in conjunction with azacitidine (AZA) and venetoclax (VEN). The trial involved patients with treatment-naïve AML who were deemed ineligible for high-intensity chemotherapy. The objective was to evaluate whether ligufalimab could provide a meaningful survival advantage and promote more profound therapeutic responses compared to standard treatment.

Key Findings About Survival Rates

At the 10-month median follow-up, the results were striking. Patients receiving ligufalimab exhibited a median event-free survival (EFS) of 9.1 months compared to just 6.9 months in the control group. This translates to a hazard ratio of 0.46, indicating a significantly lower risk of events among patients treated with ligufalimab. Furthermore, the 6-month EFS rate was reported at 67.8% for the ligufalimab group against 55.5% for the controls, showcasing its efficacy.

The study findings extended to overall survival (OS), with a median OS not yet reached in the ligufalimab cohort, contrasting with 8.3 months observed in the control group. After six months, the OS rate was significantly higher at 83.3% in the treatment group compared to 73.2% in the controls.

Efficacy of Ligufalimab in Tumor Response

Another critical outcome was the objective response rate (ORR), which showed an impressive 80% in the ligufalimab group compared to 66.7% in the control group. The composite complete response (CRc) rate also favored ligufalimab with 56.7% versus 53.3% in the control group. Notably, the rate of patients achieving CRc with minimal residual disease (MRD) negativity was significantly elevated at 46.7% in the ligufalimab cohort compared to 36.7% in the control arm. The duration of the CRc was also markedly better at 10.4 months versus 5.6 months with standard treatment, indicating lasting benefits from ligufalimab therapy.

Safety Profile and Tolerability

In terms of safety, the trial demonstrated a favorable profile for ligufalimab, with the incidence of treatment-emergent adverse events (TEAEs) being comparable across both treatment arms. Common side effects, primarily anemia, were consistent with expectations for AML and AZA+VEN therapies. While 46.7% of patients experienced anemia in the ligufalimab arm, this was almost on par with the control group at 50%. No new safety signals were identified, reinforcing the drug’s tolerability in this patient population.

Future Directions in AML Treatment

Importantly, ligufalimab has garnered Orphan Drug Designation from the U.S. FDA, emphasizing its potential in the treatment landscape of AML. Akeso is committed to advancing ligufalimab through its clinical development programs at a competitive global pace, not only for blood cancers but also for solid tumors, where it has already begun Phase III clinical trials.

The promise shown by ligufalimab signifies a major advancement in the fight against AML, potentially transforming treatment protocols and improving patient outcomes. As Akeso continues to explore the full capabilities of its novel antibody technology, the future holds great promise for innovative treatments in oncology and beyond.

About Akeso, Inc.

Founded in 2012, Akeso has established itself as a leader in the biopharmaceutical sector, developing innovative therapies to address various serious diseases including cancer and autoimmune conditions. With a strong pipeline and advanced research capabilities grounded in pioneering platform technologies, Akeso aims to provide high-quality medical solutions worldwide.

This progress in AML treatment reflects not just innovation in drug development but also the hope for patients who have long faced limited options. As this research unfolds, the medical community will watch closely to see how ligufalimab may reshape therapeutic strategies and improve lives.